The United States Food and Drug Administration (USFDA) conducted routine current Good Manufacturing Practices (cGMP) inspection at Goa manufacturing facility from 10 to 21 June 2024. On conclusion, the company received 6 inspectional observations in Form 483. The pharma company has now received communication from the USFDA stating the unit as VAI. According to media reports, 'This VAI is important milestone as it has opened the doors for the company to go ahead and launch Abraxane, a paclitaxel-based chemotherapy drug used to treat cancer with a market size of over $700 million. Currently, only Sandoz has received approval for the same in October 2024.' Cipla is a global pharmaceutical company focused on agile and sustainable growth, complex generics, and deepening portfolio in our home markets of India, South Africa, North America, and key regulated and emerging markets. The pharma major's consolidated net profit jumped 15.18% to Rs 1,302.53 crore on 5.58% rise in total revenue from operations to Rs 7,051.02 crore in Q2 FY25 over Q2 FY24.Powered by Capital Market - Live

Net profit of Cipla rose 15.18% to Rs 1302.53 crore in the quarter ended September 2024 as against Rs 1130.91 crore during the previous quarter ended September 2023. Sales rose 5.65% to Rs 6961.22 crore in the quarter ended September 2024 as against Rs 6589.22 crore during the previous quarter ended September 2023. ParticularsQuarter EndedSep. 2024Sep. 2023% Var. Sales6961.226589.22 6 OPM %27.0926.31 - PBDT2060.801884.27 9 PBT1789.061594.23 12 NP1302.531130.91 15 Powered by Capital Market - Live

Total revenue from operations grew by 5.58% year on year (YoY) to Rs 7,051.02 crore in the quarter ended 30 September 2024. Profit before tax was at Rs 1,789.06 crore in the September quarter, up 12.22% from Rs 1,594.23 crore recorded in Q2 FY24. EBITDA in Q2 FY25 stood at Rs 1,886 crore, registering a growth of 11.6% on YoY basis. EBITDA margin improved to 26.7% as compared to 26% recorded in the corresponding quarter previous year. In Q2 FY25, One India Business recorded a 5% year-on-year growth. The Branded Prescription segment continued to outperform the market in key chronic therapies, while CHL delivered strong growth of 21% YoY. However, the business faced historically slow seasonal growth in the Acute category, which impacted both the Branded Prescription and Trade Generics business. The North America business delivered quarterly revenue of $237 million, reflecting a 4% YoY increase, supported by traction in differentiated portfolio. One Africa business is Progressing on the journey of strengthening the Africa story, the North Africa business which was a part of Emerging markets and Europe is now merged with SAGA region which is renamed as One Africa. This consolidation has resulted in a robust momentum, with overall revenue growth of 22%. Emerging Markets and Europe reported strong revenue growth of 18% in USD terms. Research and development (R&D) investments stood Rs 385 crore, or 5.5% of sales, reflecting a 2% YoY increase driven by product filings and development efforts. The company maintains a strong net cash position of Rs 7,950 crore. The debt primarily consists of lease liabilities and working capital requirements. Umang Vohra, MD and Global CEO at Cipla, said, 'I am pleased to share that we continue to make considerable progress across our focused markets. In Q2 FY25, we recorded a revenue growth of 9% over last year with a highest-ever EBITDA margin of 26.7%, driven by mix and other operational efficiencies. Our One-India business was impacted during the quarter due to changed seasonal pattern, however key chronic therapies in Branded Prescription business continued to grow faster than the market. Consumer health business grew at a strong 21% YoY. With our concentrated focus in differentiated portfolio, the US business posted a revenue of $ 237 Mn. In South Africa, we recorded a solid growth of 22% YoY in local currency terms, led by Private Market. Emerging Markets and Europe delivered a robust revenue growth of 18% YoY on the back of deep market focus strategy. Going ahead, focus will be on growing our key markets, further building our flagship brands, investing in future pipeline as well as focusing on resolutions on the regulatory front'. Cipla is a global pharmaceutical company focused on agile and sustainable growth, complex generics, and deepening portfolio in our home markets of India, South Africa, North America, and key regulated and emerging markets. The scrip slipped 1.70% to Rs 1,477.90 on the BSE. Powered by Capital Market - Live

Cipla announced that Cipla (EU), wholly owned subsidiary of the Company in UK has completed all the conditions with respect to acquisition of 6.9124% equity interest in Cipla (Jiangsu) Pharmaceuticals Co., China (Cipla Jiangsu) on 25 October 2024. Cipla Jiangsu is now a wholly owned step-down subsidiary of the Company. Powered by Capital Market - Live

Cipla Ltd is down for a fifth straight session today. The stock is quoting at Rs 1529.1, down 1.46% on the day as on 13:19 IST on the NSE. The benchmark NIFTY is down around 0.2% on the day, quoting at 24804.2. The Sensex is at 81203.95, down 0.03%.Cipla Ltd has lost around 7.78% in last one month.Meanwhile, Nifty Pharma index of which Cipla Ltd is a constituent, has increased around 0.38% in last one month and is currently quoting at 23356.2, down 0.58% on the day. The volume in the stock stood at 8.48 lakh shares today, compared to the daily average of 18.45 lakh shares in last one month. The benchmark October futures contract for the stock is quoting at Rs 1530, down 1.85% on the day. Cipla Ltd jumped 29.17% in last one year as compared to a 28.64% rally in NIFTY and a 55.73% spurt in the Nifty Pharma index.The PE of the stock is 31.55 based on TTM earnings ending June 24.Powered by Capital Market - Live

Cipla Ltd is up for a third straight session today. The stock is quoting at Rs 1666.4, up 1.57% on the day as on 12:49 IST on the NSE. The benchmark NIFTY is up around 0.52% on the day, quoting at 25144.05. The Sensex is at 82028.18, up 0.48%. Cipla Ltd has gained around 2.11% in last one month. Meanwhile, Nifty Pharma index of which Cipla Ltd is a constituent, has gained around 2.22% in last one month and is currently quoting at 23307.95, up 1.99% on the day. The volume in the stock stood at 7.07 lakh shares today, compared to the daily average of 15.52 lakh shares in last one month. The benchmark October futures contract for the stock is quoting at Rs 1674.25, up 1.44% on the day. Cipla Ltd is up 44.27% in last one year as compared to a 27.7% jump in NIFTY and a 57.37% jump in the Nifty Pharma index.The PE of the stock is 33.36 based on TTM earnings ending June 24.Powered by Capital Market - Live

Cipla will hold a meeting of the Board of Directors of the Company on 29 October 2024.Powered by Capital Market - Live

Cipla Jiangsu was incorporated in China on 8th August 2019 as a joint venture between Cipla (EU) and Jiangsu Xidi Pharmaceuticals Co., (Xidi) for the purpose of manufacturing, selling and distribution of pharmaceutical products, research and development services and analytical development services. Cipla Jiangsu has set-up a manufacturing facility in China, primarily focused on inhalation respules products. Currently, Cipla EU and Xidi holds 93.0876% and 6.9124% equity interest respectively in Cipla Jiangsu. The said transaction is being carried out in terms of the existing joint venture contract between the parties and will provide Cipla EU with full control and ownership of Cipla Jiangsu. Upon completion of the transaction, Cipla Jiangsu will become a wholly owned step-down subsidiary of the company. The transaction is expected to be completed on or before 15th November 2024. Cipla is a global pharmaceutical company focused on agile and sustainable growth, complex generics, and deepening portfolio in our home markets of India, South Africa, North America, and key regulated and emerging markets. The pharma company's consolidated net profit jumped 18.27% to Rs 1177.64 crore in Q1 FY25 as against Rs 995.70 crore reported in Q1 FY24. Total revenue from operations grew by 5.77% year on year to Rs 6693.94 crore in the quarter ended 30 June 2024. The counter shed 0.17% to Rs 1,640.45 on the BSE.Powered by Capital Market - Live

Cipla announced that its wholly owned subsidiary in UK, Cipla (EU) has entered into a definitive agreement on 25 September 2024 for purchase of entire 6.9124% equity interest of Jiangsu Xidi Pharmaceuticals Co.(formerly known as Jiangsu Acebright Pharmaceuticals Co.) held in Cipla (Jiangsu) Pharmaceuticals Co., China (Cipla Jiangsu), subsidiary. Cipla Jiangsu was incorporated in China on 8th August 2019 as a joint venture between Cipla (EU) and Jiangsu XiDi Pharmaceuticals Co. (Xidi), for the purpose of manufacturing, selling and distribution of pharmaceutical products, research and development services and analytical development services. Cipla Jiangsu has set-up a manufacturing facility in China, primarily focused on inhalation respules products. Currently, Cipla EU and Xidi holds 93.0876% and 6.9124% equity interest respectively in Cipla Jiangsu. Powered by Capital Market - Live

Cipla will hold a meeting of the Board of Directors of the Company on 3 September 2024.Powered by Capital Market - Live